Follicular Lymphoma(FL), Marginal Zone Lymphoma(MZL)
Conditions
Keywords
FL, MZL, SHC014748M, Phosphatidylinositol 3-kinase (PI3K)
Brief summary
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory follicular (FL) or marginal one (MZL) lymphoma.
Detailed description
This is a phase II, multicenter study to assess the efficacy and safety of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory relapsed or refractory follicular (FL) or marginal one (MZL) lymphoma.
Interventions
DRUGSHC014748M
Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Sponsors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult, male and female volunteers, above 18 years of age inclusive. * Histologically or cytologically confirmed diagnosis of relapsed or refractory FL(grade 1, 2 or 3a) and MZL, including splenic marginal zone lymphoma(SMZL), nodal marginal zone B cell lymphoma(NMZL) and mucosa associated lymphoid tissue(MALT) lymphoma. Relapse refers to disease progression after adequate treatment to remission；refractory refers to no remission after adequate treatment. The above remission includes complete remission and partial remission. Adequate treatment refers to two or more treatments with CD20 monoclonal antibody (CDE approved for marketing) combined with alkylation agent, including but not limited to bendamustine, cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan and nitrosoureas. * Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. * Life expectancy ≥ 3 months. * Patients have at least 1 measurable lesion that measures ≥1.5 cm in a single dimension as assessed by CT or MRI. * Adequate organ function, as defined by the following values:ANC≥1.0×10\^9/L； PLT≥50×10\^9/L;Hb≥80 g/L;TBIL≤2×ULN(TBIL\>2×ULN for subjects with Gilbert syndrome,TBIL\>3×ULN for subjects with focal compression of bile duct judged by investigators); ALT and AST≤2.5×ULN(ALT and AST≤5×ULN for subjects with impaired liver function caused by hepatic infiltration);blood urea nitrogen(BUN) and Cr≤1.5×ULN;LVEF≥50%;QTcF \<450 ms for male, QTcF \<470 ms for female. * Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose, and female subjects of childbearing potential have a negative pregnancy test at baseline. * Subjects did not participate in other clinical trials within 1 month prior to study entry. * Provision of signed and dated, written informed consent prior to any study-specific evaluation.
Exclusion criteria
* Previous treatment with any PI3Kδ inhibitors. * Evidence of aggressive lymphoma(suspected clinical transformation should be conformed by biopsy). * Had any other anti-tumor treatment within 4 weeks prior to screening(including radiotherapy, chemotherapy, Chinese herbal anti-tumor treatment and major surgery); targeted therapy with 5 half-life period prior to screening. * Evidence of central nervous system involvement of the malignancy. * Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites, uncontrolled diabetes, severe or debilitating lung disease. * Any of the severe heart diseases, including New York Heart Association (NYHA) Class II or greater heart failure, arrhythmias requiring medical treatment, and history of myocardial infarction or unstable angina within 6 months prior to screening.Requiring any concomitant medication known to prolong the QT interval within 5 half-life period. * Evidence of active bacterial, fungal, or viral infection, and need systemic treatment. * Active infection with hepatitis B virus (HBV) (HBsAg positive, or HBsAg negative and HBV-DNA positive), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). * Concomitant use of any strong inhibitors or inducers of CYP3A4(except drug withdrawal prior to first dose of investigational drug. * Use of granulocyte colony-stimulating factor(G-CSF) or blood transfusion within 7 days before the hematology test at screening. * Prior autologous hematopoietic stem cell transplantation within 3 months prior to screening. * History of immune deficiency(acquired and congenital), or history of organ transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation; with active autoimmune disease or history of autoimmune disease including Interstitial pneumonia, autoimmune enteritis, autoimmune hepatitis and systemic lupus erythematosus * History of any uncured malignant tumor in the past five years except for the following: clinically cured cervical or breast carcinoma in situ, local basal cell or squamous cell carcinoma of the skin, thyroid tumor. * Inability to swallow the drug, or history of diseases affecting gastrointestinal functions significantly including malabsorption syndrome,bariatric surgery,inflammatory bowel disease, partial or complete intestinal obstruction. * Adverse events occurred during previous anticancer therapy have not been recovered to ≤1(CTCAE 5.0). * History of hypersensitivity to the main composition or any inactive excipient of the study drug. * Women who are breastfeeding. * With alcohol or drug abuse disorder. * History of stroke or intracranial hemorrhage with 6 months prior to screening. * Attenuated live vaccination within 4 weeks prior to screening. * With basic medical condition leading to risk of taking study drugs judged by investigators, or with confusion to toxicity and adverse events. * Judgment by the investigator that the patient should not participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Scale. | up to 12 months | The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on health related quality of life(HRQL) and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess non-Hodgkins lymphoma(NHL) related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). Higher scores are associated with a better quality of life. |
| Lymph Node Response (LNR) | up to 12 months | LNR was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the product of the perpendicular diameters (SPD) of measurable index lesions. |
| Time to Response (TTR) | up to 12 months | TTR was defined as the interval from the start of SHC014748M treatment to the first documentation of complete response(CR) or partial response(PR). |
| Progression-Free Survival (PFS) | up to 12 months | PFS was defined as the interval from the start of SHC014748M treatment to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using Kaplan-Meier (KM) estimates. |
| Duration of Response (DOR) | up to 12 months | DOR was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression as or death from any cause. DOR was analyzed using KM estimates. |
| Objective Response Rate (ORR) | up to 12 months | Proportion of patients who have either a complete or partial response before any treatment change. |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics Parameter: Cmax | 4 weeks |
| Pharmacokinetics Parameter: Tmax | 4 weeks |
| Pharmacokinetics Parameter: ACUlast | 4 weeks |
| Safety and Tolerability of SHC014748M Assessed as the Number of Participants Experiencing Adverse Events (AEs) or Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiograms. | up to 12 months |
Countries
China
Contacts
Primary ContactChao Wang
Backup ContactHongchan Zhang
Outcome results
None listed